Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Revenue came in at $6.5 million in Q1 2026, down 56.11% YoY from $14.7 million in Q1 2025, and down 81.79% on a QoQ basis from $35.5 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Revenue data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Revenue fell 56.11% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.4 million (up 11.07% YoY) and the FY2025 annual result came in at $74.7 million, up 26.92% from the prior year.
- Revenue retreated to $6.5 million in Q1 2026, from $35.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $35.5 million in Q4 2025 to a low of $4.5 million in Q4 2024.
- A 5-year average of $13.2 million and a median of $12.1 million in 2023 frame the typical range for Revenue.
- The widest YoY moves for Revenue: up 681.74% in 2025, down 80.16% in 2025.
- Tracing RXRX's Revenue over 5 years: stood at $13.7 million in 2022, then retreated by 20.36% to $10.9 million in 2023, then plunged by 58.26% to $4.5 million in 2024, then surged by 681.74% to $35.5 million in 2025, then sank by 81.79% to $6.5 million in 2026.
- The last three Revenue figures came in at $6.5 million (Q1 2026), $35.5 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.67 Mn |
| Mar 31, 2026 | 6.47 Mn |
| Dec 31, 2025 | 35.54 Mn |
| Sep 30, 2025 | 5.18 Mn |
| Jun 30, 2025 | 19.22 Mn |
| Mar 31, 2025 | 14.75 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 26.08 Mn |
| Jun 30, 2024 | 14.42 Mn |
| Mar 31, 2024 | 13.79 Mn |
| Dec 31, 2023 | 10.89 Mn |
| Sep 30, 2023 | 10.53 Mn |
| Jun 30, 2023 | 11.02 Mn |
| Mar 31, 2023 | 12.13 Mn |
| Dec 31, 2022 | 13.68 Mn |
| Sep 30, 2022 | 13.16 Mn |
| Jun 30, 2022 | 7.67 Mn |
| Mar 31, 2022 | 5.33 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Sep 30, 2021 | 2.53 Mn |